🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

California sues organizations for touting abortion pill reversal

Published 09/21/2023, 05:08 PM
Updated 09/21/2023, 05:15 PM
© Reuters. FILE PHOTO: A container holding boxes of Mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women's Clinic in Carbondale, Illinois, U.S., April 20, 2023. REUTERS/Evelyn Hockstein/File Photo

By Brendan Pierson

(Reuters) - California on Thursday sued two anti-abortion organizations for telling patients that they can help reverse the effects of the abortion pill mifepristone, a potentially dangerous claim not supported by evidence.

In a complaint filed in Alameda County Superior Court, California Attorney General Rob Bonta, a Democrat, accused Heartbeat International (HBI) and RealOptions Obria of violating a state law against fraudulent business practices.

"Those who are struggling with the complex decision to get an abortion deserve support and trustworthy guidance - not lies and misinformation," Bonta said in a statement.

His lawsuit seeks a court order blocking the defendants from advertising abortion pill reversal, though it does not seek to stop the practice itself.

HBI said in a statement that it had not yet been served with the lawsuit. It said women who regret taking mifepristone "deserve the right to try and save their pregnancies."

RealOptions did not immediately respond to a request for comment.

RealOptions operates five crisis pregnancy centers in California, and provides abortion pill reversal, according to the complaint. Such centers offer help to pregnant women with the goal of preventing them from having abortions.

HBI is an international anti-abortion group affiliated with more than 2,000 crisis pregnancy centers around the country. Through its website, it offers to connect women to providers who will perform abortion pill reversal.

Mifepristone is taken as the first step in medication abortion, followed by a second drug, misoprostol. Proponents of medication abortion reversal say mifepristone's effects can be blocked by a high dose of the hormone progesterone.

The only clinical trial of the process was halted early after three of 12 patients experienced severe bleeding requiring them to go to the hospital.

© Reuters. FILE PHOTO: A container holding boxes of Mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women's Clinic in Carbondale, Illinois, U.S., April 20, 2023. REUTERS/Evelyn Hockstein/File Photo

Colorado earlier this year banned the treatment. Kansas passed a law requiring healthcare providers to tell patients that medication abortion can be reversed, which Planned Parenthood is challenging.

A Texas judge in April suspended federal approval for mifepristone in response to a lawsuit by anti-abortion activists. His order is on hold while President Joe Biden's administration appeals it to the U.S. Supreme Court.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.